TG Therapeutics (TGTX) Seen Firing on All Cylinders Post-Q2 Results; Roth Affirms at 'Buy'
Tweet Send to a Friend
Roth Capital affirms TG Therapeutics (NASDAQ: TGTX) at Buy/Focus Pick with a price target of $33 amid Q2 results reported ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
